No Data
Predictive Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Predictive Oncology Announces Results Of Study Showing Long-Term Stability And Viability Of Over 150K Cryopreserved Patient Tumor Samples At Its Biobank
Predictive Oncology Study Demonstrates Long-Term Stability and Viability of Proprietary Biobank of Primary Tumor Specimens for Pharmaceutical Drug Discovery
Predictive Oncology Inc. (NASDAQ:POAI) Is Expected To Breakeven In The Near Future
Predictive Oncology Analyst Ratings
H.C. Wainwright Initiates Predictive Oncology(POAI.US) With Buy Rating, Announces Target Price $3
H.C. Wainwright analyst Swayampakula Ramakanth initiates coverage on $Predictive Oncology(POAI.US)$ with a buy rating, and sets the target price at $3.According to TipRanks data, the analyst has a
No Data
No Data